Connor, Clark & Lunn Investment Management (CC&L)’s Oscar Health OSCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11.3M Buy
+397,636
New +$8.56M 0.02% 507
2025
Q4
Sell
-107,375
Closed -$2.03M 1718
2025
Q3
$2.03M Sell
107,375
-776,914
-88% -$12.8M 0.01% 849
2025
Q2
$19M Buy
884,289
+382,317
+76% +$5.68M 0.07% 253
2025
Q1
$6.58M Buy
501,972
+79,979
+19% +$1.19M 0.03% 424
2024
Q4
$5.67M Buy
+421,993
New +$6.79M 0.03% 453
2023
Q1
Sell
-19,925
Closed -$49K 1395
2022
Q4
$49K Buy
+19,925
New +$62.3K ﹤0.01% 1151

Other funds holding OSCR

Connor, Clark & Lunn Investment Management (CC&L)'s OSCR Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Oscar Health (OSCR) in Q2 2026: 397,636 shares worth $11.3M. The stake represents 0.02% of the portfolio and ranks #507 among its holdings. This is a return to the name: Connor, Clark & Lunn Investment Management (CC&L) previously reported a position in OSCR as recently as Q3 2025.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in OSCR in Q4 2022 and has held it in 6 quarters since. The position peaked at $19M in Q2 2025. 402 funds tracked by Wall St. Rank hold OSCR as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 397,636 shares of Oscar Health worth $11.3M as of Q2 2026.
  • Oscar Health was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q2 2026.
  • Oscar Health made up 0.02% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #507 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Oscar Health in Q4 2022 and has held it in 6 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Oscar Health position peaked at $19M in Q2 2025.
  • 402 funds tracked by Wall St. Rank held Oscar Health as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.